Christianson Mark 4

What Happened
Mark Christianson, Business Development Director at NeuroOne Medical Technologies (NMTC), sold a total of 13,720 shares in two open-market transactions: 11,611 shares on 2026-03-10 for about $9,289 and 2,109 shares on 2026-03-11 for about $1,687 — roughly $10,976 in proceeds. These were sales (not purchases), which are often routine insider liquidity events rather than an explicit signal about the company.

Key Details

• Transaction dates and prices:
  • 2026-03-10: 11,611 shares sold, weighted avg price reported $0.80 (range $0.80–$0.8102 per F1).
  • 2026-03-11: 2,109 shares sold, weighted avg price reported $0.80 (range $0.80–$0.805 per F2).
• Total shares sold: 13,720; total reported proceeds ≈ $10,976.
• Shares owned after the transaction: Not specified in the provided filing.
• Footnotes: F1 and F2 state the reported prices are weighted averages of multiple transactions and list the price ranges; the reporting person will provide a per-price breakdown to the SEC on request.
• Timeliness: Form 4 filed 2026-03-12 for transactions on 2026-03-10 and 2026-03-11; filing appears timely (no late filing indicated).

Context
This filing documents outright open-market sales by a company officer. Sales are common for personal liquidity or portfolio reasons and do not by themselves indicate management’s view of company fundamentals. The amounts here are modest (~$11k total).